Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology
Conference call today, December 19, 2023, 8:30 AM ET to discuss the license agreementHOLON, Israel, Dec. 19, 2023 /PRNewswire/ -- Compugen Ltd. a clinical-stage cancer immunotherapy company and a...